Acasti Pharma Inc. (ACST) Financial Statements (2024 and earlier)
Company Profile
| Business Address |
103 CARNEGIE CENTER PRINCETON, NJ 08540 |
| State of Incorp. | QC |
| Fiscal Year End | March 31 |
| Industry (SIC) | 2834 - Pharmaceutical Preparations (benchmarking) |
| More info | Complete Financial Analysis Financial Benchmarking |
Balance Sheet (Statement of Financial Position) ($ in thousands)
| 6/30/2024 MRQ | 3/31/2024 | 12/31/2023 MRQ | 3/31/2023 | 3/31/2022 | 3/31/2021 | 3/31/2020 | |||
|---|---|---|---|---|---|---|---|---|---|
| ASSETS | |||||||||
| Current Assets | |||||||||
| Cash, cash equivalents, and short-term investments, including: | 23,005 | 25,114 | 27,890 | 43,661 | 60,700 | 14,240 | |||
| Cash and cash equivalents | 23,005 | 18,545 | 27,875 | 30,339 | 50,942 | 14,240 | |||
| Short-term investments | 6,569 | 15 | 13,322 | 9,789 | |||||
| Other undisclosed cash, cash equivalents, and short-term investments | (31) | ||||||||
| Receivables | 722 | 959 | 802 | 548 | 530 | 546 | |||
| Prepaid expense | 283 | 811 | 598 | 720 | 343 | 977 | |||
| Deferred costs | 121 | ||||||||
| Disposal group, including discontinued operation | 602 | 768 | |||||||
| Other current assets | 195 | ||||||||
| Other undisclosed current assets | 31 | ||||||||
| Total current assets: | 24,010 | 26,884 | 29,290 | 45,531 | 62,372 | 16,079 | |||
| Noncurrent Assets | |||||||||
| Operating lease, right-of-use asset | 23 | 463 | 315 | 86 | 147 | ||||
| Property, plant and equipment | 24 | 12 | 1,910 | ||||||
| Intangible assets, net (including goodwill) | 49,266 | 49,266 | 49,266 | 82,774 | 4,244 | ||||
| Goodwill | 8,138 | 8,138 | 8,138 | 12,964 | |||||
| Intangible assets, net (excluding goodwill) | 41,128 | 41,128 | 41,128 | 69,810 | 4,244 | ||||
| Other noncurrent assets | 473 | ||||||||
| Other undisclosed noncurrent assets | 104 | ||||||||
| Total noncurrent assets: | 49,290 | 49,301 | 49,833 | 83,089 | 86 | 6,774 | |||
| TOTAL ASSETS: | 73,300 | 76,185 | 79,123 | 128,620 | 62,458 | 22,853 | |||
| LIABILITIES AND EQUITY | |||||||||
| Liabilities | |||||||||
| Current Liabilities | |||||||||
| Accounts payable and accrued liabilities, including: | 1,684 | 1,746 | 3,336 | 3,156 | 1,493 | 7,319 | |||
| Employee-related liabilities | ✕ | ✕ | ✕ | ✕ | 1,182 | 771 | 1,359 | ||
| Accounts payable | 1,007 | 913 | 1,242 | 1,678 | 115 | 1,713 | |||
| Accrued liabilities | 176 | 532 | 946 | 296 | 607 | 4,247 | |||
| Other undisclosed accounts payable and accrued liabilities | 501 | 301 | 1,148 | ||||||
| Other undisclosed current liabilities | 24 | 75 | 104 | 86 | 76 | ||||
| Total current liabilities: | 1,684 | 1,770 | 3,411 | 3,260 | 1,579 | 7,395 | |||
| Noncurrent Liabilities | |||||||||
| Long-term debt and lease obligation: | 191 | 71 | |||||||
| Liabilities, other than long-term debt | 9,873 | 9,735 | 7,757 | 16,899 | 5,219 | 2,393 | |||
| Deferred income tax liabilities | 5,514 | 6,403 | 7,347 | 16,889 | |||||
| Operating lease, liability | 410 | 191 | 71 | ||||||
| Derivative instruments and hedges, liabilities | 4,359 | 3,332 | 10 | 5,219 | 2,393 | ||||
| Total noncurrent liabilities: | 9,873 | 9,735 | 7,757 | 17,090 | 5,219 | 2,464 | |||
| Total liabilities: | 11,557 | 11,505 | 11,168 | 20,350 | 6,798 | 9,859 | |||
| Equity | |||||||||
| Equity, attributable to parent, including: | 61,743 | 64,680 | 67,955 | 108,270 | 55,660 | 12,994 | |||
| Common stock | 258,294 | 257,990 | 197,194 | 137,424 | |||||
| Additional paid in capital | 17,862 | 17,633 | 13,965 | 12,154 | 10,817 | 9,797 | |||
| Accumulated other comprehensive loss | (6,038) | (6,038) | (6,038) | (6,037) | (6,333) | (7,887) | |||
| Accumulated deficit | (211,119) | (207,953) | (198,266) | (155,837) | (146,018) | (126,340) | |||
| Other undisclosed equity, attributable to parent | 261,038 | 261,038 | |||||||
| Total equity: | 61,743 | 64,680 | 67,955 | 108,270 | 55,660 | 12,994 | |||
| TOTAL LIABILITIES AND EQUITY: | 73,300 | 76,185 | 79,123 | 128,620 | 62,458 | 22,853 | |||
Income Statement (P&L) ($ in thousands)
| 6/30/2024 TTM | 3/31/2024 | 12/31/2023 TTM | 3/31/2023 | 3/31/2022 | 3/31/2021 | 3/31/2020 | ||
|---|---|---|---|---|---|---|---|---|
| Revenues | (75) | 147 | 196 | |||||
| Other income | 147 | |||||||
| Cost of revenue (Cost of Goods and Services Sold) | (76) | |||||||
| Gross profit: | 147 | 120 | ||||||
| Operating expenses | (11,347) | (40,951) | (46,929) | (15,340) | (10,836) | (24,438) | ||
| Other undisclosed operating loss | (1,505) | (6,711) | (5,226) | (396) | (5,703) | |||
| Operating loss: | (12,852) | (47,662) | (52,155) | (15,589) | (16,419) | (24,438) | ||
| Nonoperating income (expense) | (1,833) | (926) | 184 | 5,122 | (3,259) | (1,075) | ||
| Investment income, nonoperating | 911 | 849 | 246 | 77 | 107 | 336 | ||
| Gain (loss), foreign currency transaction, before tax | (16) | (10) | (77) | 71 | (1,490) | (2) | ||
| Interest and debt expense | (46) | |||||||
| Loss from continuing operations before equity method investments, income taxes: | (14,685) | (48,588) | (51,971) | (10,467) | (19,678) | (25,559) | ||
| Other undisclosed income from continuing operations before income taxes | 46 | |||||||
| Loss from continuing operations before income taxes: | (14,685) | (48,588) | (51,971) | (10,467) | (19,678) | (25,513) | ||
| Income tax benefit | 1,832 | 9,814 | 9,542 | 648 | ||||
| Loss from continuing operations: | (12,853) | (38,774) | (42,429) | (9,819) | (19,678) | (25,513) | ||
| Loss before gain (loss) on sale of properties: | ✕ | ✕ | ✕ | ✕ | (9,819) | (19,678) | (25,513) | |
| Net loss available to common stockholders, diluted: | (12,853) | (38,774) | (42,429) | (9,819) | (19,678) | (25,513) | ||
Comprehensive Income ($ in thousands)
| 6/30/2024 TTM | 3/31/2024 | 12/31/2023 TTM | 3/31/2023 | 3/31/2022 | 3/31/2021 | 3/31/2020 | ||
|---|---|---|---|---|---|---|---|---|
| Net loss: | (12,853) | (38,774) | (42,429) | (9,819) | (19,678) | (25,513) | ||
| Comprehensive loss, net of tax, attributable to parent: | (12,853) | (38,774) | (42,429) | (9,819) | (19,678) | (25,513) | ||
Statements Sources
The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.